Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
29 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Altimmune, Inc.’s names, not what it holds today.
Patents granted
29
29 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 2 in 2023
Applications published
43
4 of them in 2025
Names they are printed under
7
its own name, a subsidiary, a former name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
Altimmune Inc. its own name
US, as the owner printed on each patent
10 publishedAltimmune UK Limited a subsidiary
GB, as the owner printed on each patent
8 publishedSpitfire Pharma LLC a subsidiary
US, as the owner printed on each patent
8 publishedAltimmune, Inc its own name
named as the applicant on its applications, in US
8 publishedAltimmune UK Limited a subsidiary
named as the applicant on its applications, in GB
6 publishedPharmAthene, Inc. a former name
US, as the owner printed on each patent
1 publishedSpitfire Pharma LLC a subsidiary
named as the applicant on its applications, in US
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 25, 2025 | 12,257,229 | Peptide pharmaceuticals for treatment of NASH and other disorders | Pharmaceuticals | Spitfire Pharma LLC |
| Dec 24, 2024 | 12,171,806 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | Pharmaceuticals | Spitfire Pharma LLC |
| Mar 5, 2024 | 11,918,645 | Vaccines against hepatitis B virus | Pharmaceuticals | Altimmune UK Limited |
| May 16, 2023 | 11,648,305 | Fluorocarbon-linked peptide formulation | Pharmaceuticals | Altimmune UK Limited |
| Jan 3, 2023 | 11,541,028 | Peptide pharmaceuticals for treatment of NASH and other disorders | Pharmaceuticals | Altimmune Inc. |
| Jul 26, 2022 | 11,395,802 | Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof | Pharmaceuticals | Altimmune Inc. |
| Jul 12, 2022 | 11,382,969 | Vaccines against Hepatitis B virus | Pharmaceuticals | Altimmune UK Limited |
| Jul 12, 2022 | 11,382,968 | Coronavirus immunogenic compositions and uses thereof | Pharmaceuticals | Altimmune Inc. |
| Oct 12, 2021 | 11,141,477 | Rapid and prolonged immunologic-therapeutic | Pharmaceuticals | Altimmune Inc. |
| Jul 20, 2021 | 11,066,353 | Antigen delivery vectors and constructs | Pharmaceuticals | Altimmune UK Limited |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 4, 2025 | 2025/0367263 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | Pharmaceuticals | Spitfire Pharma LLC |
| Sep 18, 2025 | 2025/0288650 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | Pharmaceuticals | Spitfire Pharma LLC |
| Aug 21, 2025 | 2025/0262280 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | Pharmaceuticals | Spitfire Pharma LLC |
| May 1, 2025 | 2025/0134963 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | Pharmaceuticals | Spitfire Pharma LLC |
| Aug 22, 2024 | 2024/0277815 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | Pharmaceuticals | Spitfire Pharma LLC |
| Aug 15, 2024 | 2024/0269238 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | Pharmaceuticals | Spitfire Pharma LLC |
| May 9, 2024 | 2024/0148879 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | Pharmaceuticals | Spitfire Pharma LLC |
| Feb 8, 2024 | 2024/0042007 | Fluorocarbon-Linked Peptide Formulation | Pharmaceuticals | Altimmune UK Limited |
| May 4, 2023 | 2023/0136261 | METHODS AND COMPOSITIONS FOR VIRAL VECTORED GnRH VACCINES TO CONTROL REPRODUCTION AND BREEDING BEHAVIOR IN MAMMALS | Pharmaceuticals | Altimmune, Inc |
| Apr 6, 2023 | 2023/0104501 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | Pharmaceuticals | Spitfire Pharma LLC · patent 12,171,806 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 8.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.